INTRODUCTION
The incidence of female cancer is increasing, which is a serious threat to women's health. Among them, cervical cancer, endometrial cancer, ovarian cancer and breast cancer, are the most common malignant tumors. With the development of medical technology, gynecological cancers (GCs) have been studied more and better. For example, cervical cancer and endometrial cancer can be detected early, but it does not reduce its incidence. Ovarian cancer is difficult to detect early, is the leading cause of gynecological cancer deaths. Early detection of molecular markers is the most effective method of GCs prevention; however the molecular mechanisms underlying GCs progression are not well characterized. Therefore, a better understanding of the molecular mechanisms involved in GCs development and progression will provide diagnostic and prognostic markers and potential targets for the therapeutic intervention of GCs.
Ultraconserved elements (UCEs) are noncoding gene sequences with strict conserved across among humans,
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mice and rats. Emerging evidence demonstrates that UCEs can encode non-protein-coding RNAs (ncRNAs) serve as modulators of gene expression [1, 2] . Previous studies showed that transcribed ultraconserved elements (TUCEs) serve as oncogenes or tumor suppressor genes in development of tumor. For example, uc.73 and uc.338 modulates cell proliferation, apoptosis and metastasis in colorectal cancer (CC) cell lines [3, 4] . Uc.206 acts as a novel oncogene by targeting the P53 gene and promoting CC cell growth [5] .
Uc. 189 located in 6p21 is a member of the UCEs. Previous studies showed uc.189 were overexpressed in liver cancer and cervical cancer [6, 7] . It indicates that uc.189 might be an oncogenic gene. However, uc.189 has not been investigated in gynecological cancers before. According to that, we hypothesis that uc.189 may be overexpressed in gynecological cancers.
In the current study, the expression of uc.189 in human tumor samples of different GCs including CSCC, EAC, OCA and corresponding normal tissues was identified using UCEs locked nucleic acid (LNA) in situ hybridization, and evaluated its relationship with clinicopathologic parameters and prognosis. To the best of our knowledge, this is the first study to investigate the expression of uc.189 and its clinicopathologic significance in gynecological cancers.
RESULTS

Expression of uc.189 in CSCC, EAC and OCA
The clinic pathologic parameters were listed in Tables 1, 2 and Supplementary Table 1 . Uc.189 was mainly located in the cytoplasm of tumor cells from gynecological cancers and neighboring normal tissue ( Figure 1 ). In CSCC, uc.189 expression was increased in 78.5% of cases (91/116), decreased in 4.3% (5/116), and unchanged in 17.2% (20/116) . In EAC its expression was increased in 74.5% (73/98), decreased in 3.1% (3/98), and unchanged in 22.4% (22/98). Expression of uc.189 was increased in 23, and unchanged/decreased in 6, of 29 cases of OCA. Aberrant uc.189 expression was thus detected in most gynecological cancer tissues, and its expression was increased in the majority of cases of CSCC, EAC, and OCA (P < 0.01).
Relevance of uc.189 expression and clinicopathologic variables in CSCC and EAC
There was a significant difference in Tumor grade (χ 2 = 10.736, P = 0.001), nodal status (χ 2 = 3.868, P = 0.049), TNM stage (χ 2 = 12.318, P = 0.000) between patients with low/ unchanged versus high expression levels of uc.189 in CSCC. In EAC, unchanged/low versus high expression levels of uc.189 also showed a significant difference in tumor size (χ 2 = 29.518, P = 0.000), tumor grade (χ 2 = 36.993, P = 0.000), TNM stage (χ 2 = 39.674, P = 0.002) and distant metastasis (χ 2 = 40.462, P = 0.000). But no significant correlations between uc.189 expression levels and other clinicopathologic variables, including age and depth of tumor invasion (all P > 0.05; Tables 3, 4 ).
Survival analysis
In survival analysis, patient follow-up times were ranging from 6-84 months for CSCC and 12-84.5 months for EAC (Tables 1, 2 and Supplementary Table 1) . KaplanMeier analysis demonstrated that high expression of uc.189, node status, and distant metastasis were significant positive prognostic predictors for OS in patients with CSCC (P = 0.000, P = 0.001, P = 0.000, respectively) and those with EAC (P = 0.000, P = 0.005, P = 0.013, respectively). Other clinicopathologic characteristics, including age, tumor status, location, and TNM stage were not significantly associated with prognosis in CSCC or EAC (P > 0.05; Tables 5, 6 ), but in EAC tumor size and grade were significant difference (P = 0.000, P = 0.000), there was a tendency towards a difference in TNM stage between patients with high versus low/ unchanged expression levels of uc.189 in CSCC (P = 0.083).
The prognosis of CSCC patients with high expression of uc.189 was significantly poorer than that of CSCC patients with low/ unchanged uc.189 expression (P < 0.001; Figure 2 ). The median survival times were 43.45 months for high uc.189 expression and 72.47 months for low/unchanged uc.189 expression. Similarly, tumor node status (44.69 vs. 58.67 months; P < 0.01, n = 116) and distant metastasis (45.34 vs.54.61 months; P < 0.01, n = 116) also remained a significant predictor of poor survival from Table 5 .
The prognosis of EAC patients with high uc.189 expression was dramatically poorer than that of EAC patients with low/unchanged uc.189 expression (P < 0.01; Figure 2 ). The median survival times were 43.52 months for high uc.189 expression and 72.99 months for low/unchanged uc.189 expression. Similarly, tumor node status (44.69 vs. 58.67 months; P < 0.01, n = 98) and distant metastasis (45.34 vs.54.61 months; P < 0.01, n = 98) also remained a significant predictor of poor survival from Table 5 .
In multivariate analysis for CSCC, tumor stage (HR, 5.825; 95% CI, 1.893-17.930; P = 0.002), grade (HR, 0.515; 95% CI, 0.271-0.978; P = 0.042), distant metastasis (HR, 0.298; 95% CI, 0.099-0.899; P = 0.032), and high uc.189 (HR, 0.067; 95% CI, 0.027-0.165; P = 0.000) predicted poor prognosis (Table 7) . Moreover, in multivariate analysis for EAC, tumor status (HR,1.759; 95% CI, 1.084-2.854; P = 0.022), stage (HR, 2.515; 95% CI, 1.002-6.318; P = 0.050), high uc.189 (HR, 0.015; 95% CI, 0.005-0.046; P = 0.000), and tumor grade (HR, www.impactjournals.com/oncotarget 2.791; 95% CI, 1.403-5.549; P = 0.03) predicted poor prognosis (Table 8) .
DISCUSSION
The main common malignant neoplasms of female reproductive system are endometrial carcinoma, cervical and ovarian cancer. Endometrial carcinoma is generally found early, but the prognosis of patients' with recurrence and metastasis in this cancer is significantly poor [8] . With the wide application of cervical cytological screening, prevention of cervical cancer has made great progress, but chemotherapy is still the main treatment for patients with advanced cervical cancer [9] . The main type of ovarian cancer includes serous, mucinous and endometrial, the survival rate of patients is still low although surgery and drug treatment progress for ovarian carcinomas [10] .
Ultraconserved elements (UCEs) are noncoding DNA regions with strict conserved across among mice, rats, and humans. Transcribed UCEs can encode non-protein-coding RNAs (ncRNAs) serve as modulators of transcription and translation of mRNAs [11] [12] [13] . By regulating protein production, many UCEs serve as oncogenes or tumor suppressor genes [14, 15] . uc.73 modulates cell proliferation and apoptosis in colorectal cancer cell lines [3] . In bladder cancer tissues, upregulation of uc.8 was inversely related to grade and stage [16] , but silence of uc.8 inhibited the proliferation, invasion and migration of cancer cells [17] . Uc.338 is an important oncogene which increased expression of MMP9 to improve invasion and migration of cancer cells in colorectal carcinoma [4] , low-expression of uc.73 closely related with stage and grade of colorectal neoplasia [3] . Over-expression of uc.63 suppressed apoptosis of B lymphoma cells and might be predict poor prognosis [18] . Uc.206 acts as a novel oncogene by targeting the P53 gene and promoting CC cell growth, which might be beneficial for cervical cancer therapy [5] . However, little is known about the expression level and biological role of uc.189 in gynecological carcinomas.
This study is the first to systematically explore the expression of uc.189 and its association with clinicopathologic features and prognosis of CSCC, EAC, and In conclusion, our results indicate that gynecological system cancers, especially cases of CSCC and EAC with high uc.189 expression compared with neighboring normal tissues, have a relatively poor prognosis, whereas low or unchanged uc.189 expression is associated with a better prognosis.
Although further studies are needed to confirm this work, these results suggest that uc.189 may represent a valuable independent prognostic indicator, as well as a potential target for the treatment of gynecological carcinomas.
MATERIALS AND METHODS
Tumor tissue collection
A total of 243 samples including 116 cervical squamous cell carcinomas (CSCCs), 98 endometrial adenocarcinomas (EACs), 29 ovarian cystoadenocarcinomas(OCAs), and corresponding normal tissues were used in this study and obtained from 243 patients of gynecological carcinomas (age range, 32-79 years) at the Departments of gynecology of The Affiliated Hospital of Yangzhou University, Yangzhou University (Yangzhou, China). The absence of tumor tissues 
Tissue microarray
Tissue microarrays were constructed using appropriate tissue cores from formalin-fixed and paraffinembedded samples as described previously [18] . Briefly, appropriate tumor areas and corresponding non-tumor gastric samples were selected by pathologists and a single core (diameter 0.6 mm) was taken from each tissue. Tissue microarray blocks were constructed using an automated tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). The array blocks were cut into 5-μm sections, and the sections were stained with hematoxylin and eosin to verify the presence of tumor cells. In all cases, tissue cores obtained from normal adjacent tissue served as internal controls.
In situ hybridization
In situ hybridization was performed using Digoxin random primer marker oligonucleotide for uc.189 with scramble-UCE as a negative control and In situ hybridization kit (Boster Biological Technology co. ltd., WuHan, China).A solution of 20 nM probes in hybridization buffer was applied to the array slides, which were covered with Nescofilm (Boster, China) and overnight at 55°C in a humidified chamber. Hybridized probes were detected by incubation with anti-digoxigenin-biotin conjugate at 37°C for 30 min, followed by 3, 3'-diaminobenzidine (DAB) stain to develop a brownish yellow color. Finally, the cells were counterstained with hematoxylin for 3-5 min and mounted on slides. (−), 2-3 indicated weak expression (+), 4-5 indicated moderate expression (++), and 6 indicated strong expression (+++). Each sample was examined separately and scored by two pathologists [19] [20] .
In this analysis, differences in the expression level of uc.189 in tumor tissues are expressed relative to the level of uc.189 in adjacent normal tissues. The expression of uc.189 in normal mucosal samples were judged as positive or negative by the staining status.
Statistical analysis
All statistical analyses were performed using the SPSS software package (SPSS Inc., Chicago, IL, USA, version 16.0). Associations between clinicopathologic parameters and uc.189 expression were analyzed using χ2-tests. When sample numbers in some categorical cells were lower than 5, the Fisher's exact test was employed. Overall survival was calculated and survival curves were plotted using the Kaplan-Meier method; differences between groups were compared using log-rank tests. Significant variables in univariate models were further analyzed by multivariate Cox proportional hazards regression models to identify independent prognostic factors. All tests were two-sided and P values < 0.05 were considered statistically significant.
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